Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer

Jiang,Jianping; Mo,Weiqiang; Lian,Xue; Cao,Dakui; Cheng,Haiying; Wang,Haiqin

doi:10.3892/etm.2024.12583

Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer

Authors:
- Jianping Jiang
- Weiqiang Mo
- Xue Lian
- Dakui Cao
- Haiying Cheng
- Haiqin Wang
View Affiliations

Affiliations: Department of Respiratory Medicine, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China, Department of Nursing Administration, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China
Published online on: May 22, 2024 https://doi.org/10.3892/etm.2024.12583
Article Number: 294
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to assess the roles of peripheral circulating tumor cell (CTC) count, CTC subtypes and programmed death ligand 1 (PD‑L1) expression in the clinical staging and prognosis of patients with non‑small cell lung cancer (NSCLC). A total of 100 patients with NSCLC with available tumor tissues were enrolled in the present study, and 7.5 ml peripheral blood was collected. Patients were divided into PD‑L1‑positive and PD‑L1‑negative groups according to PD‑L1 immunohistochemical staining. Peripheral blood samples from both groups were analyzed to determine the CTC count, epithelial‑type CTCs (E‑CTCs), mesenchymal‑type CTCs (M‑CTCs) and PD‑L1 expression. Clinical data were collected, and patients were followed up for a maximum of 36 months, with patient death as the endpoint event. Patients with PD‑L1‑positive tumors had a worse prognosis compared with those with PD‑L1‑negative tumors (P=0.045). The PD‑L1‑positive group exhibited significantly higher numbers of CTCs and M‑CTCs compared with the PD‑L1‑negative group (P≤0.05). However, the number of E‑CTCs did not differ significantly between the two groups (P>0.05). PD‑L1‑positive patients with higher CTC and M‑CTC counts had relatively poorer prognoses (P≤0.05), while the number of E‑CTCs had no significant effect on prognosis (P>0.05). Compared with the early‑stage NSCLC group, the late‑stage NSCLC group exhibited a significant increase in the CTC count (P≤0.05), while E‑CTC and M‑CTC counts did not significantly differ between the two groups (P>0.05). The PD‑L1‑positive group exhibited a significant increase in the number of PD‑L1+ CTCs and PD‑L1⁺ M‑CTCs compared with the PD‑L1‑negative group (P≤0.05), while PD‑L1⁺ E‑CTC counts did not differ significantly between the two groups (P>0.05). The PD‑L1‑positive patients with a higher number of PD‑L1+ CTCs and PD‑L1⁺ M‑CTCs had relatively poorer prognoses (P≤0.05), while the PD‑L1+ E‑CTC count had no significant effect on prognosis (P>0.05). Compared with the early‑stage NSCLC group, the late‑stage NSCLC group exhibited a significant increase in the number of PD‑L1+ CTCs and PD‑L1⁺ M‑CTCs (P≤0.05), while PD‑L1⁺ E‑CTC counts did not significantly differ between the two groups (P>0.05). Based on univariate and multivariate analyses, the number of PD‑L1⁺ M‑CTCs was identified as an independent prognostic factor for NSCLC. In conclusion, the presence of CTCs in peripheral blood, particularly PD‑L1⁺ M‑CTC subtype, indicated poorer clinical staging and prognosis in patients with NSCLC. These findings suggested that CTCs, specifically the PD‑L1⁺ M‑CTC subtype, could serve as a monitoring indicator for the clinical staging and prognosis of patients with NSCLC.

View Figures

View References

1	Adjei AA: Lung cancer worldwide. J Thorac Oncol. 14(956)2019.PubMed/NCBI View Article : Google Scholar
2	Thai AA, Solomon BJ, Sequist LV, Gainor JF and Heist RS: Lung cancer. Lancet. 398:535–554. 2021.PubMed/NCBI View Article : Google Scholar
3	Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P and Fintelmann FJ: Lung cancer screening. Lancet. 401:390–408. 2023.PubMed/NCBI View Article : Google Scholar
4	Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W and Yao H: Association of survival and Immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: A Meta-analysis and individual patient-level analysis. JAMA Netw Open. 2(e196879)2019.PubMed/NCBI View Article : Google Scholar
5	Steven A, Fisher SA and Robinson BW: Immunotherapy for lung cancer. Respirology. 21:821–833. 2016.PubMed/NCBI View Article : Google Scholar
6	Rupp B, Ball H, Wuchu F, Nagrath D and Nagrath S: Circulating tumor cells in precision medicine: Challenges and opportunities. Trends Pharmacol Sci. 43:378–391. 2022.PubMed/NCBI View Article : Google Scholar
7	Aceto N: Bring along your friends: Homotypic and heterotypic circulating tumor cell clustering to accelerate metastasis. Biomed J. 43:18–23. 2020.PubMed/NCBI View Article : Google Scholar
8	Gires O, Pan M, Schinke H, Canis M and Baeuerle PA: Expression and function of epithelial cell adhesion molecule EpCAM: Where are we after 40 years? Cancer Metastasis Rev. 39:969–987. 2020.PubMed/NCBI View Article : Google Scholar
9	Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, et al: Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 7:306–315. 2012.PubMed/NCBI View Article : Google Scholar
10	Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y and Zhou J: Circulating tumor cells: Biology and clinical significance. Signal Transduct Target Ther. 6(404)2021.PubMed/NCBI View Article : Google Scholar
11	Bae SY, Kamalanathan KJ, Galeano-Garces C, Konety BR, Antonarakis ES, Parthasarathy J, Hong J and Drake JM: Dissemination of circulating tumor cells in breast and prostate cancer: Implications for early detection. Endocrinology. 165(bqae022)2024.PubMed/NCBI View Article : Google Scholar
12	Mitra A, Mishra L and Li SL: EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 6:10697–10711. 2015.PubMed/NCBI View Article : Google Scholar
13	Joosse SA, Gorges TM and Pantel K: Biology, detection, and clinical implications of circulating tumor cells. Embo Mol Med. 7:1–11. 2015.PubMed/NCBI View Article : Google Scholar
14	Zhang X, Wei L, Li J, Zheng J, Zhang S and Zhou J: Epithelial-mesenchymal transition phenotype of circulating tumor cells is associated with distant metastasis in patients with NSCLC. Mol Med Rep. 19:601–608. 2019.PubMed/NCBI View Article : Google Scholar
15	Zhang Y, Men Y, Wang J, Xing P, Zhao J, Li J, Xu D, Hui Z and Cui W: Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. J Cancer Res Clin Oncol. 148:1137–1146. 2022.PubMed/NCBI View Article : Google Scholar
16	Pantazaka E, Vardas V, Roumeliotou A, Kakavogiannis S and Kallergi G: Clinical relevance of mesenchymal- and stem-associated phenotypes in circulating tumor cells isolated from lung cancer patients. Cancers (Basel). 13(2158)2021.PubMed/NCBI View Article : Google Scholar
17	Bie F, Tian H, Sun N, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhou B and Gao S: Research progress of Anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC. Front Oncol. 12(769124)2022.PubMed/NCBI View Article : Google Scholar
18	Hu CB, Huang C, Wang J, Hong Y, Fan DD, Chen Y, Lin AF, Xiang LX and Shao JZ: PD-L1/BTLA checkpoint axis exploited for bacterial immune escape by restraining CD8+ T Cell-initiated adaptive immunity in Zebrafish. J Immunol. 211:816–835. 2023.PubMed/NCBI View Article : Google Scholar
19	Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ and Sharpe AH: PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 214:895–904. 2017.PubMed/NCBI View Article : Google Scholar
20	Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A and Walker J: PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 112:200–215. 2017.PubMed/NCBI View Article : Google Scholar
21	Barclay J, Creswell J and León J: Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway. Arch Esp Urol. 71:393–399. 2018.PubMed/NCBI
22	Ligero M, Serna G, El Nahhas OSM, Sansano I, Mauchanski S, Viaplana C, Calderaro J, Toledo RA, Dienstmann R, Vanguri RS, et al: Weakly supervised deep learning predicts immunotherapy response in solid tumors based on PD-L1 expression. Cancer Res Commun. 4:92–102. 2024.PubMed/NCBI View Article : Google Scholar
23	Hou F, Qi C, Lu Y, Li F and Hao Z: Cell HE staining smears and paired cell paraffin sections in detection of epithelial growth factor receptor gene of pleural fluid specimens. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 47:35–44. 2022.PubMed/NCBI View Article : Google Scholar : (In English, Chinese).
24	Davies CR, Guo T, Burke E, Stankiewicz E, Xu L, Mao X, Scandura G, Rajan P, Tipples K, Alifrangis C, et al: The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer. Front Oncol. 12(1060864)2023.PubMed/NCBI View Article : Google Scholar
25	Castro-Giner F and Aceto N: Tracking cancer progression: From circulating tumor cells to metastasis. Genome Med. 12(31)2020.PubMed/NCBI View Article : Google Scholar
26	Zhang H, Yuan F, Qi Y, Liu B and Chen Q: Circulating tumor cells for Glioma. Front Oncol. 11(607150)2021.PubMed/NCBI View Article : Google Scholar
27	Liang DH, Hall C and Lucci A: Circulating tumor cells in breast cancer. Recent Results Cancer Res. 215:127–145. 2020.PubMed/NCBI View Article : Google Scholar
28	Pantel K: Circulating tumor cells in head and neck carcinomas. Clin Chem. 65:1193–1195. 2019.PubMed/NCBI View Article : Google Scholar
29	Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R and Ardizzoni A: Circulating tumor cells in genitourinary tumors. Ther Adv Urol. 10:65–77. 2018.PubMed/NCBI View Article : Google Scholar
30	Castello A, Carbone FG, Rossi S, Monterisi S, Federico D, Toschi L and Lopci E: Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors. Cancers (Basel). 12(487)2020.PubMed/NCBI View Article : Google Scholar
31	Chen M, Xu R, Wu L and Chen X: Relationship between circulating tumor cells undergoing EMT and short-term efficacy following interventional treatment in patients with hepatocellular carcinoma. J Interv Med. 3:146–150. 2020.PubMed/NCBI View Article : Google Scholar
32	Thunnissen E, de Langen AJ and Smit EF: PD-L1 IHC in NSCLC with a global and methodological perspective. Lung Cancer. 113:102–105. 2017.PubMed/NCBI View Article : Google Scholar
33	Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni P, Qin A, Zhao L, Azizi E, Lawrence TS, Ramnath N, et al: PD-L1 expression in circulating tumor cells increases during Radio(chemo)therapy and indicates poor prognosis in Non-small cell lung cancer. Sci Rep. 9(566)2019.PubMed/NCBI View Article : Google Scholar
34	Cheng Y, Wang T, Lv X, Li R, Yuan L, Shen J, Li Y, Yan T, Liu B and Wang L: Detection of PD-L1 expression and its clinical significance in circulating tumor cells from patients with Non-small-cell lung cancer. Cancer Manag Res. 12:2069–2078. 2020.PubMed/NCBI View Article : Google Scholar